ROAD MAP
Part 1
Mar 6, 2017 A good explanation of green teas strengths over other antioxidant rich foods for use in the product Phytofare. Phytofare® has been clinically proven in human studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the original product as developed by, Plandaí Biotechnology, focused on selling Phytofare® as an ingredient to manufacturers in the nutraceuticals industry, Plandaí SA will target the pharmaceutical market with a finished product.
Part 2
Mar 7, 2017 Protext CEO discusses its lead product Phytofare® and how green tea catechins (antioxidants) if delivered with greater bioavailability, has significant benefits and advantages over the way traditional green tea is consumed. Phytofare® green tea catechin complex in capsule form taken daily can help aid as a preventative measure as well as help combat metabolic syndrome causes especially for type II Diabetes but also includes wellness benefits in addressing high blood pressure, cholesterol, and weight issues.
Part 3
Mar 29, 2017 Protext Mobility releases video interview w/ CEO discussing Cannabis Biosciences acquisition, science behind Phytofare, cannabis research, and exciting future of TXTM.
Part 4
May 12, 2017 Roger Duffield shares with investors and shareholders more details on TXTM’s progress with medical marijuana license in South Africa.
Part 5
May 13, 2017 Roger Duffield finishing the interview explaining the details on Cannabis Bioscience’s medical marijuana license in South Africa.
Part 6
Aug 1, 2017 Video Update from 7/26/17 – TXTM CEO Roger Duffield at site location where cannabis operations to take place. Subsequently, all final documents requested by Ministry of Health have been submitted for license issuance
Part 7
Jul 26, 2018 Part 1 of 2, TXTM, Protext Pharma CEO update on medical cannabis license in South Africa.
Part 8
Jul 26, 2018 TXTM, Protext Pharma CEO updates part 2 of 2 on Medical Cannabis License in South Africa.
Part 9 – April 30, 2020
Republic of South Africa Medical Marijuana Dispensaries (RSAMMD) Signs Letter of Intent with USA-based Protext Pharma (TXTM) for Commercialization of Next Generation Live Cannabis and Hemp Extraction Technology
Part 10 – May 7, 2020
Republic of South Africa Medical Marijuana Dispensaries (RSAMMD) Announces Successful Testing Results of Proprietary Cannabis Plant Extraction Technology with JV Partner Protext Pharma (TXTM)
Part 11 “Roger Duffield’s Blessing”
Dear: Dylon
I cannot help you anymore with your development work as my health and other challenges are my priority, my research with cannabis stopped 4 years ago when I first became ill and I cannot add to the findings and application submitted to SAPHRA at that time, You have the methodology to produce the liquid phase from which you have to remove the solids, oil and phytonutrient phases.
Dr J has the wherewithal to conduct these experiments and has other supporting equipment such as Super Critical Extract which may play a significant part
I wish you all the best with your investigations
Science is very challenging and especially cannabinoids so you will need to remain focused on the prime objective.
Part 12 – 13 June 2022
REPUBLIC OF SOUTH AFRICA MEDICAL MARIJUANA DISPENSARIES ACQUISITIONS LLC (RSAMMDA.LLC) COMPLETES ACQUISITION OF PROTEXT MOBILITY, INC. (TXTM)
Part 13 – 17 June 2022
Republic of South Africa Medical Marijuana Dispensaries Acquisitions LLC (rsammda.llc) to discuss its recent acquisition of Protext Mobility, inc. (TXTM) at the emerging growth conference Wednesday June 22, 2022 12:30pm est
Part 14 – 30 June 2022
RSAMMD Acquisitions LLC and Protext Mobility, Inc. (TXTM) pleased to announce its chairman Dr. Ahmed Jamaloodeen has received the high honor of being appointed as national commodity board chairman of cannabis and all indigenous flora
Part 15 – Where Protext Mobility INC – (Protext Pharma) Was Prior to Merger
- Current $TXTM Balance sheet
- No Operating Cash
- No Web Site
- Limited Staff
- No Permits/No Licenses to legally conduct cannabis tests on Extraction equipment
- No Biomass
- No Farm Land
- No Facilities/Offices
- No Equipment/Machinery
- No Kettles
- No Expertise or Qualifications
- No Sales Team
- No Marketing Team
- No Work has been Conducted on Extraction Equipment before RSAMMD JV
- No Rodger Duffield
Part 16 – Where Protext Mobility INC – (Protext Pharma) is Now After Merger with RSAMMDA
What $TXTM was not able to obtain before RSAMMDA Merger highlighting the True Value of the Human CAPITAL in creating ACCESS to the following
- Kettle
- Farm Land 5000 Hectares
- Cannabis/Hemp Permits
- Dispensing License
- Biomass
- Seeds
- Intellectual Property
- Qualifications
- Government
- Union
- Contacts
- Products Development
- Products to Market (Local & Export)
- Global Distribution
- Export Permits
- Import Permits to Europe, USA, Caribbean, South America, Australia, Singapore onto the East.
- Equates to increase in shareholder value
Part 17 – RSAMMD ACQUISITIONS LLC AND PROTEXT MOBILITY, INC. (TXTM) PROVIDE SHAREHOLDERS UPDATE AND NEAR TERM ROAD MAP. 01 Aug 2022
Bright Future Ahead for $TXTM Global Healing & Humanity as a Whole. #LetsGo #TXTMTribe
Join the Future of
Cannabis Medicine
Be part of our mission to revolutionize botanical medicine
through innovative extraction technologies and scientific research.
